Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune response to SARS-CoV-2 mRNA vaccination in adult patients with cancer
2021-003710-39Phase 4Completed
- Sponsor
- Institut Jules Bordet
- Start
- Oct 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tozinameran, elasomeran, Comirnaty Bivalent Original/Omicron BA.4/BA.5, davesomeran, raxtozinameran and 1 more in coronavirus disease 2019 (COVID-19), sponsored by Institut Jules Bordet. Primary endpoint: Detectable anti-spike antibody titer at baseline. Started Oct 2021; status: completed.
02
Drugs
tozinameranelasomeranComirnaty Bivalent Original/Omicron BA.4/BA.5davesomeranraxtozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-003710-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003710-39.